NASDAQ:CABA

Cabaletta Bio Stock Insider Trading

Healthcare > Biotechnology

Buy CABA

*Your capital is at risk

$3.02

+0.0100 (+0.332%)

At Close: Jun 23, 2026

Cabaletta Bio Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -42.37. In total, the insiders bought 5.12M and sold 2.73M CABA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-42.37
● Buy	5.12M shares
● Sell	2.73M shares
63% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Mar 02, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -42.37. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Brun Scott C. Director	Director	22 000 Value: $70.8K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Tomasello Shawn Director	Director	22 000 Value: $70.8K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Simon Mark Director	Director	22 000 Value: $70.8K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Henriques Richard C Jr Director	Director	22 000 Value: $70.8K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Bollard Catherine Director	Director	22 000 Value: $70.8K
Mar 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Nichtberger Steven President & CEO	CEO / President	674 000 Value: $2.22M
Mar 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Gerard Michael General Counsel	Officer	175 000 Value: $577.5K
Mar 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Das Arun Chief Business Officer	Officer	175 000 Value: $577.5K
Mar 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Marda Anup Chief Financial Officer	C-Suite Officer	225 000 Value: $742.5K
Mar 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Chang David J. Chief Medical Officer	Officer	225 000 Value: $742.5K
Mar 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Binder Gwendolyn President, Science & Tech.	CEO / President	225 000 Value: $742.5K
Jan 21, 2026 Buy	Common Stock P-Purchase	Gerard Michael General Counsel	Officer	6 600 Value: $15.0K
Jan 21, 2026 Buy	Common Stock P-Purchase	Bollard Catherine Director	Director	4 405 Value: $10K
Jan 21, 2026 Buy	Common Stock P-Purchase	Binder Gwendolyn President, Science & Tech.	CEO / President	11 312 Value: $24.8K
Jan 21, 2026 Buy	Common Stock P-Purchase	Gavel Steve Chief Commercial Officer	Officer	22 170 Value: $50.2K
Jan 21, 2026 Buy	Common Stock P-Purchase	Simon Mark Director	Director	11 061 Value: $25.3K
Jan 21, 2026 Buy	Common Stock P-Purchase	Tomasello Shawn Director	Director	22 725 Value: $50.3K
Jan 21, 2026 Buy	Common Stock P-Purchase	Chang David J. Chief Medical Officer	Officer	8 800 Value: $19.9K
Jan 21, 2026 Buy	Common Stock P-Purchase	Nichtberger Steven President & CEO	CEO / President	45 000 Value: $100.8K
Oct 13, 2025 Buy	Stock Option (Right to Buy) A-Award	Gavel Steve Chief Commercial Officer	Officer	275 000 Value: $684.8K
Oct 13, 2025 Buy	Common Stock J-Other	Gavel Steve Insider	Other	0 Value: $0
Oct 13, 2025 Buy	Common Stock J-Other	Gavel Steve Insider	Other	0 Value: $0
Oct 13, 2025 Buy	Stock Option (Right to Buy) A-Award	Gavel Steve Chief Commercial Officer	Officer	275 000 Value: $684.8K
Jun 09, 2025 Buy	Stock Option (Right to Buy) A-Award	Simon Mark Director	Director	22 000 Value: $52.1K
Jun 09, 2025 Buy	Stock Option (Right to Buy) A-Award	Brun Scott C. Director	Director	22 000 Value: $52.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CABALETTA BIO, INC.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART,...

Read Full Profile Here